Feds Subpoena Cephalon Over Treanda Marketing

NEW YORK, Sept. 26, 2011 - In an SEC filing, Cephalon said it has received a subpoena from the DOJ requesting records regarding its marketing of leukemia drug Treanda. An excerpt of the filing is below. The filing can be linked to here.

 

On September 23, 2011, Cephalon, Inc. (the "Company") received a subpoena duces tecum from the U.S. Attorney's Office for the Southern District of New York pursuant to its authority under the Health Insurance Portability and Accountability Act requesting records regarding TREANDA® (bendamustine hydrochloride). The Company is in the process of responding to the subpoena and intends to cooperate fully.

Posted: September 2011


View comments

Hide
(web1)